TriLink BioTechnologies Plays Key Role in Published Study on Single-Cell Sequencing

(November 29, 2018) -

TriLink BioTechnologies, a Maravai LifeSciences company and a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that the company’s CleanTag® Small RNA Library Prep Kit was the enabling technology in a new study of next-generation sequencing of small RNAs from single cells. The study, Efficient Production of On-Target Reads for Small RNA Sequencing of Single Cells Using Modified Adapters, demonstrates the successful sequencing of small RNA at the single-cell level, a process that had previously proven challenging. The paper was published in the October issue of Analytical Chemistry and the research team included scientists from Stanford University, Jordan University of Science and Technology, NIST, San Jose State University, University of Minnesota, Riken and TriLink BioTechnologies.



"Single-cell sequencing is an increasingly popular area of research, as investigations strive to uncover cell-to-cell variations," said Anton P. McCaffrey, Ph.D., senior director of emerging science and innovation for TriLink. "The sequencing of single cells is challenging due to the low levels of input RNA. Traditional methods sequence bulk cells, which give results in terms of averages, masking cellular heterogeneity."

The work described in the paper uses a streamlined workflow based on TriLink’s CleanTag Small RNA Library Prep Kit. CleanTag allows sequencing of very small RNA inputs from single cells or biofluids. "We believe this is the first report of sequencing of small RNAs from the cytoplasm of a single cell,” said McCaffrey. “This will allow a number of new applications, including the study of circulating tumor cells."                                                                                                                                                                                                                 


About TriLink BioTechnologies


Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of DNA and RNA for research, diagnostics, therapeutics and OEM customers. Specializing in the manufacture of highly modified nucleic acids such as mRNA and custom oligonucleotides, TriLink products are instrumental in the fields of gene and oligonucleotide therapy, nucleoside chemotherapy, gene editing and diagnostics. The company is ISO 9001:2015 certified and operates cGMP suites for manufacturing. TriLink is headquartered in San Diego, where it also maintains its manufacturing facilities. The company was acquired by Maravai LifeSciences in 2016.



Contacts for the media:


Jennifer Dahlgren
Dahlgren Communications
530-263-6817
[email protected]



David Weber, Chief Commercial Officer
Maravai LifeSciences
(650) 464-4908
[email protected]